STAAR Surgical (NASDAQ:STAA) Rating Lowered to Neutral at Mizuho

STAAR Surgical (NASDAQ:STAA) was downgraded by analysts at Mizuho from an “outperform” rating to a “neutral” rating in a research note issued on Wednesday, MarketBeat reports. They presently have a $17.00 target price on the medical instruments supplier’s stock, down from their prior target price of $45.00. Mizuho’s price objective would indicate a potential upside of 6.52% from the stock’s current price.

A number of other research analysts have also commented on STAA. BTIG Research lowered STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a report on Tuesday, January 7th. Canaccord Genuity Group cut their price target on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a report on Monday, December 9th. Stephens raised shares of STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. Finally, William Blair lowered shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $26.86.

STAAR Surgical Trading Down 3.2 %

STAA stock opened at $15.96 on Wednesday. The firm’s 50-day moving average price is $23.57 and its two-hundred day moving average price is $29.15. The stock has a market capitalization of $786.51 million, a price-to-earnings ratio of 36.27 and a beta of 0.62. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $52.68.

Insider Buying and Selling

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 53,500 shares of the business’s stock in a transaction on Monday, December 16th. The shares were acquired at an average price of $24.24 per share, for a total transaction of $1,296,840.00. Following the completion of the acquisition, the insider now owns 10,821,931 shares in the company, valued at $262,323,607.44. This trade represents a 0.50 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired a total of 105,876 shares of company stock worth $2,487,168 in the last three months. 1.00% of the stock is owned by corporate insiders.

Institutional Trading of STAAR Surgical

A number of hedge funds have recently made changes to their positions in the stock. Arcadia Investment Management Corp MI bought a new position in STAAR Surgical during the 3rd quarter valued at approximately $37,000. Quarry LP purchased a new position in shares of STAAR Surgical in the 3rd quarter worth about $50,000. Quest Partners LLC purchased a new position in shares of STAAR Surgical in the 3rd quarter worth about $128,000. Van ECK Associates Corp boosted its stake in STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock worth $129,000 after purchasing an additional 393 shares in the last quarter. Finally, nVerses Capital LLC grew its position in STAAR Surgical by 78.3% during the 3rd quarter. nVerses Capital LLC now owns 4,100 shares of the medical instruments supplier’s stock valued at $152,000 after purchasing an additional 1,800 shares during the last quarter. 96.70% of the stock is owned by institutional investors.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.